
Sequencing CELMoDs and Prioritizing Current Treatment Needs in Relapsed/Refractory Multiple Myeloma
In Round 2 of the Hot Topics Debate, Teams Compass and Catalyst discuss how clinicians should approach treatment sequencing at first relapse in relapsed/refractory multiple myeloma, balancing immediate disease control with future treatment options.
Episodes in this series

In Round 2 of the Hot Topics Debate, Teams Compass and Catalyst discuss how clinicians should approach treatment sequencing at first relapse in relapsed/refractory multiple myeloma, balancing immediate disease control with future treatment options. Team Compass emphasizes the potential role of CELMoD-based regimens in providing effective disease control while preserving subsequent treatment options, including CAR T-cell therapy and bispecific antibodies. Faculty discusses how these regimens may be used independently of prior or subsequent treatment choices and may offer an option for patients previously treated with T-cell-redirecting therapies. Team Catalyst argues that clinicians should prioritize the most effective treatment for the current relapse rather than reserving specific therapies for later lines, given the rapidly evolving treatment landscape and the possibility that patients may not require additional treatment. The discussion highlights the importance of tumor biology, disease aggressiveness, and the potential to achieve deep, durable responses when selecting therapy. Faculty emphasize individualizing treatment decisions while recognizing that future treatment needs and available options may change.
Related to this article








